In recent years, NMO has raised enormous interest among scientists and clinical neurologists, fueled by the detection of a highly specific serum immunoglobulin G autoantibody targeting the astrocytic water channel aquaporin‐4 (AQP4) by Dr. Lennon and colleagues in 2004 (Jarius & Wildemann, 2013; Lennon et al., 2004; Lennon, Kryzer, Pittock, Verkman, & Hinson, 2005). The gene discussed is AQP4; the disease is neuromyelitis optica.